Skip to content

Total at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s total?
Denali Therapeutics Inc. (DNLI) reported total of $664.17M in Q1 2026.
How has Denali Therapeutics Inc.'s total changed year-over-year?
Denali Therapeutics Inc.'s total decreased by 33.2% year-over-year, from $994.43M to $664.17M.
What is the long-term trend for Denali Therapeutics Inc.'s total?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s total has grown at a -5.3% compound annual growth rate (CAGR), from $995.15M to $759.84M.